by Katrina Carr | Nov 10, 2020 | Diagnosis & Therapy
COVID-19 crisis changed treatment for most lung cancer patients BY TED BOSWORTH credit: FG Trade/Getty Images At a cancer treatment center that tracked data prospectively, the COVID-19 epidemic led directly to treatment delays and reduced surveillance in the majority...
by Katrina Carr | Oct 6, 2020 | Diagnosis & Therapy
Lung cancer screening model identifies more at-risk African Americans BY WALTER ALEXANDER credit: THEPALMER/Getty Images A new model for lung cancer screening may ensure that African Americans at risk for lung cancer are no longer undercounted, according to...
by Katrina Carr | Jan 15, 2020 | Diagnosis & Therapy
Treatment landscape changes but challenges persist for ROS1 or NTRK fusion–positive lung cancer BY ANDREW D. BOWSER MDedge News Patients with non–small cell lung cancer harboring ROS1 or NTRK fusions may face a particularly challenging journey. These cancers, while...
by Katrina Carr | Nov 4, 2019 | Diagnosis & Therapy
Adding durvalumab to EP for ES-SCLC improves overall survival BY SHARON WORCESTER Adding durvalumab immunotherapy to etoposide and platinum (EP) for the first-line treatment for extensive-stage small cell lung cancer (ES-SCLC) significantly improved 18-month overall...
by Katrina Carr | Oct 30, 2019 | Diagnosis & Therapy
Maintenance immunotherapy fails in SCLC BY WILL PASS MDedge News Maintenance immunotherapy offers no added survival benefit in patients with extensive disease small cell lung cancer (ED-SCLC), according to results from the CheckMate 451 trial. The phase 3 results...
by Katrina Carr | May 28, 2019 | Diagnosis & Therapy
Checkpoint inhibitor shows efficacy in third line for SCLC By Neil Osterweil MDedge News The immune checkpoint inhibitor pembrolizumab produced durable objective responses in some patients with extensive-stage small-cell lung cancer (SCLC) who had disease progression...
